Equities

Yield10 Bioscience Inc

YTEN:QBB

Yield10 Bioscience Inc

Actions
  • Price (USD)0.99
  • Today's Change-0.16 / -13.91%
  • Shares traded8.78k
  • 1 Year change-88.06%
  • Beta1.3713
Data delayed at least 15 minutes, as of Sep 20 2024 20:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).

  • Revenue in USD (TTM)750.00k
  • Net income in USD-12.70m
  • Incorporated1998
  • Employees29.00
  • Location
    Yield10 Bioscience Inc19 Presidential WayWOBURN 01801United StatesUSA
  • Phone+1 (617) 583-1700
  • Fax+1 (302) 655-5049
  • Websitehttps://www.yield10bio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NovAccess Global Inc0.00-1.74m441.57k1.00---------0.1193-0.11930.00-0.22460.00----0.00-1,836.30-2,185.89-------------------------177.93------
Endonovo Therapeutics Inc255.72k-4.40m444.45k0.00------1.74-0.0652-0.06520.0003-0.0720.2256-------388.54-303.26----96.2174.38-1,722.26-5,956.27---1.38----85.15---495.02------
Herborium Group, Inc.340.33k-318.65k545.97k2.00------1.60-0.3492-0.34920.3672-1.162.323.8925.94---216.97-490.56----58.3156.36-93.63-186.810.0331-39.14----19.45-18.15120.44------
Drazcanna Inc2.05m-5.71m562.15k--------0.2746-0.7024-0.70240.24920.10040.685--23.88---191.19---643.20---11.20---279.10-----33.040.2445--------------
Capstone Therapeutics Corp0.00-358.00k580.00k2.00---------6.58-38.120.00-60.700.00-------113.46141.94-199.60173.06-----------2.92--------52.46------
GlobeStar Therapeutics Corp0.00-1.98m639.61k-----------0.0023-0.00230.00-0.00150.00-------38,103.72-4,657.88-------7,790.20---2,834,410.00---21.00---------31.01------
Yield10 Bioscience Inc750.00k-12.70m650.59k29.00------0.8675-135.92-135.921.95-9.710.1697----25,862.07-287.44-91.26---108.09-----1,693.60-2,279.74---------86.67-35.94-6.55--1.84--
International Stem Cell Corp8.32m-529.00k712.39k29.00------0.0856-0.0661-0.06611.040.03551.462.5411.31286,965.50-12.02-29.22-84.86-73.8258.6259.49-8.22-21.010.4785-3.940.9254---4.78-6.8260.42---34.45--
PaxMedica Inc0.00-18.15m745.47k6.00--0.6011-----11.19-11.190.000.15940.00----0.00-474.77-755.77-781.78-------------3,015.030.00-------23.56------
VBI Vaccines Inc9.41m-83.99m745.74k131.00------0.0792-6.93-6.930.4818-0.21660.09231.4037.0571,839.70-81.40-46.58-171.57-58.62-24.06-277.46-881.79-2,755.980.2116-1.601.13--702.4020.9417.18---32.07--
Entero Therapeutics Inc0.00-6.44m816.78k15.00--0.0413-----51.90-51.900.0038.450.00----0.00-12.74-295.92-14.01-1,599.51-----------265.690.0802-------7.55------
Molecular Pharmacology (USA) Ltd0.00-105.18k899.60k0.00---------0.0009-0.00090.00-0.01880.00-------976.60-1,219.29------------------------44.29------
Data as of Sep 20 2024. Currency figures normalised to Yield10 Bioscience Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Tidal Investments LLCas of 05 Sep 20248.000.00%
G1 Execution Services LLCas of 30 Jun 20240.000.00%
Birchview Capital LPas of 30 Jun 20240.000.00%
Qube Research & Technologies Ltd.as of 30 Jun 20240.000.00%
XTX Markets LLCas of 30 Jun 20240.000.00%
Jane Street Capital LLCas of 30 Jun 20240.000.00%
Two Sigma Securities LLCas of 30 Jun 20240.000.00%
BBVA Asset Management SA SGIICas of 30 Jun 20240.000.00%
Ulland Investment Advisors LLCas of 30 Jun 20240.000.00%
Cutter & Co. Brokerage, Inc. (Investment Management)as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.